Table 2.

Summary of clinical variables in the cost-effectiveness modelling analysis

Variable	p	Reference
Age (years)	49.9	Turkish Oncotype-Dx Decision Impact Study8
Net change in chemotherapy use with low RS (%)	−20.9	Holt et al. 201113
Net change in chemotherapy use with intermediate RS (%)	1.90	Holt et al. 201113
Net change in chemotherapy use with high RS (%)	4.76	Holt et al. 201113
10-year risk of recurrence (low RS) on HT (%)	3.20	Paik et al. 20063
10-year risk of recurrence (intermediate RS) on HT (%)	9.10	Paik et al. 20063
10-year risk of recurrence (high RS) on HT (%)	39.5	Paik et al. 20063
RRR with chemotherapy (low RS) (%)	0	Assumed based on Paik et al. 20063
RRR for chemotherapy (intermediate RS) (%)	39.0	Paik et al. 20063
RRR for chemotherapy (high RS) (%)	74.0	Paik et al. 20063
Post-recurrence survival (years)	3.3	Thomas et al. 200912
Mortality rates	-	TÜİK (2013)11

HT: hormone/endocrine therapy; RRR: relative risk reduction; RS: Recurrence Score